Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I. Ibusuki R, et al. Among authors: tsuchiya kawano y. Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215. doi: 10.21037/tlcr-22-393. Transl Lung Cancer Res. 2022. PMID: 36519019 Free PMC article.
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I. Tsuchiya-Kawano Y, et al. Oncologist. 2020 Jun;25(6):475-e891. doi: 10.1634/theoncologist.2019-0746. Epub 2019 Oct 24. Oncologist. 2020. PMID: 31649134 Free PMC article. Clinical Trial.
Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Takada K, et al. Int J Cancer. 2021 Jul 15;149(2):473-482. doi: 10.1002/ijc.33557. Epub 2021 Mar 26. Int J Cancer. 2021. PMID: 33720422 Free article.
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy.
Takada K, Takamori S, Shimokawa M, Toyokawa G, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Takada K, et al. ESMO Open. 2022 Feb;7(1):100348. doi: 10.1016/j.esmoop.2021.100348. Epub 2021 Dec 20. ESMO Open. 2022. PMID: 34942439 Free PMC article.
A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.
Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Takada K, et al. Among authors: tsuchiya kawano y. BMC Cancer. 2022 May 6;22(1):503. doi: 10.1186/s12885-022-09385-8. BMC Cancer. 2022. PMID: 35524214 Free PMC article.
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.
Takada K, Buti S, Bersanelli M, Shimokawa M, Takamori S, Matsubara T, Takenaka T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Nakanishi Y, Okamoto I, Pinato DJ, Cortellini A, Yoshizumi T. Takada K, et al. Among authors: tsuchiya kawano y. Eur J Cancer. 2022 Sep;172:199-208. doi: 10.1016/j.ejca.2022.06.002. Epub 2022 Jun 30. Eur J Cancer. 2022. PMID: 35780526
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Chihara Y, Takeda T, Goto Y, Nakamura Y, Tsuchiya-Kawano Y, Nakao A, Onoi K, Hibino M, Fukuda M, Honda R, Yamada T, Taniguchi R, Sakamoto S, Date K, Nagashima S, Tanzawa S, Minato K, Nakatani K, Izumi M, Shimose T, Kishimoto J, Uchino J, Takayama K. Chihara Y, et al. Among authors: tsuchiya kawano y. Oncologist. 2022 Nov 3;27(11):903-e834. doi: 10.1093/oncolo/oyac193. Oncologist. 2022. PMID: 36181763 Free PMC article. Clinical Trial.
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Uematsu S, et al. Among authors: tsuchiya kawano y. Thorac Cancer. 2023 Jan;14(2):168-176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21. Thorac Cancer. 2023. PMID: 36408699 Free PMC article.
17 results